[1] Patent: CN105906621, 2016, A. Location in patent: Paragraph 0019
[2] Patent: WO2005/42464, 2005, A1. Location in patent: Page/Page column 32-33
[3] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 8, p. 1858 - 1868
[4] Patent: WO2009/30725, 2009, A2. Location in patent: Page/Page column 58
[5] Patent: EP1857444, 2007, A1. Location in patent: Page/Page column 20
[6]
Andaloussi, M., Moreau, E., Masurier, N., Lacroix, J., Gaudreault, R. C., Chezal, J.-M., Laghdach, A. E., Canitrot, D., Debiton, E., Teulade, J.-C., & Chavignon, O. (2008). Novel imidazo[1,2-a]naphthyridinic systems (part 1): Synthesis, antiproliferative and DNA-intercalating activities. European Journal of Medicinal Chemistry, 43(11), 2505–2517.
https://doi.org/10.1016/j.ejmech.2008.02.017 [7]
Filla, S. A., Mathes, B. M., Johnson, K. W., Phebus, L. A., Cohen, M. L., Nelson, D. L., Zgombick, J. M., Erickson, J. A., Schenck, K. W., Wainscott, D. B., Branchek, T. A., Schaus, J. M. (2003). Novel Potent 5-HT
1F Receptor Agonists: Structure−Activity Studies of a Series of Substituted
N-[3-(1-Methyl-4-piperidinyl)-1
H-pyrrolo[3,2-
b]pyridin-5-yl]amides. Journal of Medicinal Chemistry, 46(14), 3060–3071.
https://doi.org/10.1021/jm030020m